|
|
| Type |
Oral Presentation |
| Area |
Bioconjugation |
| Room No. |
403호 |
| Time |
THU 09:50-: |
| Code |
BIO.O-5 |
| Subject |
Design of the Well-Defined Antibody-Drug Conjugates (ADCs) :
Preclinical Development of an anti-HER2 ADC, LCB14-0110 |
| Authors |
송호영
(주)레고켐 바이오사이언스 신약연구소, Korea |
| Abstract |
LegoChem Biosciences has developed a novel, next-generation site-specific antibody-drug conjugates (ADCs) platform technology called ConjuallTM which enables the generation of homogenous ADCs with specifically defined number of payload only at the intended sites on the antibody employed. This presentation will also illustrate a novel linker chemistry that shows superb plasma stability. With the result, we have developed preclinical candidate, LCB14-0110 which is highly efficacious, site-specific, and plasma-stable anti-HER2 ADC. |
| E-mail |
hysong@legochembio.com |
|
119th General Meeting of the KCS